DBV Technologies S.A. (NASDAQ:DBVT) Receives $14.75 Consensus Target Price from Brokerages

Shares of DBV Technologies S.A. (NASDAQ:DBVT) have earned an average rating of “Hold” from the seven research firms that are covering the company, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell recommendation, one has assigned a hold recommendation, three have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $14.75.

A number of research analysts have issued reports on DBVT shares. Wall Street Zen lowered shares of DBV Technologies from a “hold” rating to a “sell” rating in a research note on Friday, July 18th. Lifesci Capital upgraded shares of DBV Technologies to a “strong-buy” rating in a research note on Thursday, June 26th. JMP Securities restated a “market outperform” rating and set a $21.00 price target on shares of DBV Technologies in a research note on Thursday, June 26th. Zacks Research upgraded shares of DBV Technologies from a “strong sell” rating to a “hold” rating in a research note on Monday, September 29th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of DBV Technologies in a research note on Wednesday.

DBV Technologies Stock Down 5.5%

NASDAQ DBVT opened at $15.00 on Friday. DBV Technologies has a 52 week low of $2.20 and a 52 week high of $16.98. The firm has a market cap of $411 million, a PE ratio of -3.14 and a beta of -0.45. The company has a 50 day moving average price of $10.23 and a 200 day moving average price of $9.44.

DBV Technologies (NASDAQ:DBVT) last issued its quarterly earnings results on Tuesday, July 29th. The company reported ($1.55) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.21) by ($1.34). DBV Technologies had a negative net margin of 3,220.49% and a negative return on equity of 287.15%. The company had revenue of $1.74 million for the quarter, compared to analyst estimates of $0.64 million. On average, equities research analysts anticipate that DBV Technologies will post -7.05 earnings per share for the current fiscal year.

Institutional Trading of DBV Technologies

Large investors have recently made changes to their positions in the business. Adage Capital Partners GP L.L.C. purchased a new stake in shares of DBV Technologies in the 2nd quarter valued at $9,659,000. MPM Bioimpact LLC purchased a new stake in shares of DBV Technologies in the 2nd quarter valued at $9,649,000. Octagon Capital Advisors LP purchased a new stake in shares of DBV Technologies in the 2nd quarter valued at $9,315,000. Vivo Capital LLC purchased a new stake in shares of DBV Technologies in the 2nd quarter valued at $9,659,000. Finally, Nan Fung Trinity HK Ltd. purchased a new stake in shares of DBV Technologies in the 2nd quarter valued at $340,000. 71.74% of the stock is owned by hedge funds and other institutional investors.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.